Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Nivolumab (and other agents affecting the anti-programmed death-1 [anti-PD-1] pathway) have
demonstrated anti-tumor activity in multiple tumor types including non-small cell lung cancer
(NSCLC), melanoma (MEL), renal cell carcinoma (RCC), and other cancers. However, there
remains a large proportion of participants who do not achieve durable clinical benefit to
nivolumab monotherapy. Combinations of immune-oncology (IO) agents with complimentary
mechanisms as well as radiation represent a promising strategy to improve response rates to
immunotherapy. In this phase I study, radiation will be used in combination with IO agents
nivolumab and anti-IL-8 (BMS-986253) to assess toxicity by organ system. The study will
determine the safe doses of radiation by organ site in conjunction with nivolumab and
BMS-986253. The study will also provide the opportunity to evaluate changes in the tumor
microenvironment induced by the treatment.